Angela Hwang
CIK 1725474 · President, Global Biopharma · last filed 2026-05-08
Angela Hwang is a President, Global Biopharma who has filed 25 SEC Form 4 insider transactions across 2 companies since 2018. The most recent filing, for UPS, was dated May 8, 2026. Across all open-market trades the lifetime net is −$1.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.24M
2
25
-$1.30M
Holdings By Company
Recent Filings
25 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-08 | UPS | Grant (A) | — | $0 | EDGAR |
| 2025-05-09 | UPS | Grant (A) | — | $0 | EDGAR |
| 2024-05-03 | UPS | Grant (A) | — | $0 | EDGAR |
| 2023-05-11 | PFE | Disc (I) | — | $0 | EDGAR |
| 2023-05-05 | UPS | Grant (A) | — | $0 | EDGAR |
| 2023-02-28 | PFE | Mixed | +5,510 | -$167.5K | EDGAR |
| 2023-02-24 | PFE | Mixed | +14,273 | -$137.3K | EDGAR |
| 2022-05-09 | UPS | Grant (A) | — | $0 | EDGAR |
| 2022-03-01 | PFE | Mixed | +3,318 | -$140.3K | EDGAR |
| 2022-02-25 | PFE | Mixed | +6,677 | -$150.8K | EDGAR |